Literature DB >> 27210756

High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells.

Jidnyasa Ingale1, Armando Stano1, Javier Guenaga2, Shailendra Kumar Sharma2, David Nemazee1, Michael B Zwick1, Richard T Wyatt3.   

Abstract

A major step toward an HIV-1 vaccine is an immunogen capable of inducing neutralizing antibodies. Envelope glycoprotein (Env) mimetics, such as the NFL and SOSIP designs, generate native-like, well-ordered trimers and elicit tier 2 homologous neutralization (SOSIPs). We reasoned that the display of well-ordered trimers by high-density, particulate array would increase B cell activation compared to soluble trimers. Here, we present the design of liposomal nanoparticles displaying well-ordered Env spike trimers on their surface. Biophysical analysis, cryo- and negative stain electron microscopy, as well as binding analysis with a panel of broadly neutralizing antibodies confirm a high-density, well-ordered trimer particulate array. The Env-trimer-conjugated liposomes were superior to soluble trimers in activating B cells ex vivo and germinal center B cells in vivo. In addition, the trimer-conjugated liposomes elicited modest tier 2 homologous neutralizing antibodies. The trimer-conjugated liposomes represent a promising initial lead toward the development of more effective HIV vaccine immunogens.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27210756      PMCID: PMC4889521          DOI: 10.1016/j.celrep.2016.04.078

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  38 in total

1.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Authors:  Robert Pejchal; Laura M Walker; Robyn L Stanfield; Sanjay K Phogat; Wayne C Koff; Pascal Poignard; Dennis R Burton; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

Review 2.  Germinal centers.

Authors:  Gabriel D Victora; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

3.  Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Authors:  Xueling Wu; Tongqing Zhou; Jiang Zhu; Baoshan Zhang; Ivelin Georgiev; Charlene Wang; Xuejun Chen; Nancy S Longo; Mark Louder; Krisha McKee; Sijy O'Dell; Stephen Perfetto; Stephen D Schmidt; Wei Shi; Lan Wu; Yongping Yang; Zhi-Yong Yang; Zhongjia Yang; Zhenhai Zhang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Melissa Simek; Dennis R Burton; Wayne C Koff; Nicole A Doria-Rose; Mark Connors; James C Mullikin; Gary J Nabel; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

4.  Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Authors:  Jean-Philippe Julien; Albert Cupo; Devin Sok; Robyn L Stanfield; Dmitry Lyumkis; Marc C Deller; Per-Johan Klasse; Dennis R Burton; Rogier W Sanders; John P Moore; Andrew B Ward; Ian A Wilson
Journal:  Science       Date:  2013-10-31       Impact factor: 47.728

5.  HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.

Authors:  Yuxing Li; Sijy O'Dell; Richard Wilson; Xueling Wu; Stephen D Schmidt; Carl-Magnus Hogerkorp; Mark K Louder; Nancy S Longo; Christian Poulsen; Javier Guenaga; Bimal K Chakrabarti; Nicole Doria-Rose; Mario Roederer; Mark Connors; John R Mascola; Richard T Wyatt
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

6.  B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates.

Authors:  Takayuki Ota; Colleen Doyle-Cooper; Anthony B Cooper; Katherine J Doores; Miyo Aoki-Ota; Khoa Le; William R Schief; Richard T Wyatt; Dennis R Burton; David Nemazee
Journal:  J Immunol       Date:  2013-08-12       Impact factor: 5.422

7.  Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Authors:  Mahboobeh Safaeian; Carolina Porras; Yuanji Pan; Aimee Kreimer; John T Schiller; Paula Gonzalez; Douglas R Lowy; Sholom Wacholder; Mark Schiffman; Ana C Rodriguez; Rolando Herrero; Troy Kemp; Gloriana Shelton; Wim Quint; Leen-Jan van Doorn; Allan Hildesheim; Ligia A Pinto
Journal:  Cancer Prev Res (Phila)       Date:  2013-11

8.  Structural mechanism of trimeric HIV-1 envelope glycoprotein activation.

Authors:  Erin E H Tran; Mario J Borgnia; Oleg Kuybeda; David M Schauder; Alberto Bartesaghi; Gabriel A Frank; Guillermo Sapiro; Jacqueline L S Milne; Sriram Subramaniam
Journal:  PLoS Pathog       Date:  2012-07-12       Impact factor: 6.823

9.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus.

Authors:  Hua-Xin Liao; Rebecca Lynch; Tongqing Zhou; Feng Gao; S Munir Alam; Scott D Boyd; Andrew Z Fire; Krishna M Roskin; Chaim A Schramm; Zhenhai Zhang; Jiang Zhu; Lawrence Shapiro; James C Mullikin; S Gnanakaran; Peter Hraber; Kevin Wiehe; Garnett Kelsoe; Guang Yang; Shi-Mao Xia; David C Montefiori; Robert Parks; Krissey E Lloyd; Richard M Scearce; Kelly A Soderberg; Myron Cohen; Gift Kamanga; Mark K Louder; Lillian M Tran; Yue Chen; Fangping Cai; Sheri Chen; Stephanie Moquin; Xiulian Du; M Gordon Joyce; Sanjay Srivatsan; Baoshan Zhang; Anqi Zheng; George M Shaw; Beatrice H Hahn; Thomas B Kepler; Bette T M Korber; Peter D Kwong; John R Mascola; Barton F Haynes
Journal:  Nature       Date:  2013-04-03       Impact factor: 49.962

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  69 in total

1.  Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations.

Authors:  Jacob T Martin; Christopher A Cottrell; Aleksandar Antanasijevic; Diane G Carnathan; Benjamin J Cossette; Chiamaka A Enemuo; Etse H Gebru; Yury Choe; Federico Viviano; Stephanie Fischinger; Talar Tokatlian; Kimberly M Cirelli; George Ueda; Jeffrey Copps; Torben Schiffner; Sergey Menis; Galit Alter; William R Schief; Shane Crotty; Neil P King; David Baker; Guido Silvestri; Andrew B Ward; Darrell J Irvine
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

2.  Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses.

Authors:  Joseph D Bazzill; Sabrina M Stronsky; Laura C Kalinyak; Lukasz J Ochyl; Jesse T Steffens; Sean A van Tongeren; Christopher L Cooper; James J Moon
Journal:  Nanomedicine       Date:  2018-11-22       Impact factor: 5.307

3.  Dense Array of Spikes on HIV-1 Virion Particles.

Authors:  Armando Stano; Daniel P Leaman; Arthur S Kim; Lei Zhang; Ludovic Autin; Jidnyasa Ingale; Syna K Gift; Jared Truong; Richard T Wyatt; Arthur J Olson; Michael B Zwick
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

Review 4.  Surface engineering for lymphocyte programming.

Authors:  Elana Ben-Akiva; Randall A Meyer; David R Wilson; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2017-05-10       Impact factor: 15.470

Review 5.  The Density Code for the Development of a Vaccine?

Authors:  Wei Cheng
Journal:  J Pharm Sci       Date:  2016-09-17       Impact factor: 3.534

Review 6.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

Review 7.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

8.  Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation.

Authors:  Hannah G Kelly; Hyon-Xhi Tan; Jennifer A Juno; Robyn Esterbauer; Yi Ju; Wenbo Jiang; Verena C Wimmer; Brigette C Duckworth; Joanna R Groom; Frank Caruso; Masaru Kanekiyo; Stephen J Kent; Adam K Wheatley
Journal:  JCI Insight       Date:  2020-05-21

9.  Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.

Authors:  Paola Martinez-Murillo; Karen Tran; Javier Guenaga; Gustaf Lindgren; Monika Àdori; Yu Feng; Ganesh E Phad; Néstor Vázquez Bernat; Shridhar Bale; Jidnyasa Ingale; Viktoriya Dubrovskaya; Sijy O'Dell; Lotta Pramanik; Mats Spångberg; Martin Corcoran; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

10.  Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer.

Authors:  Peng Zhang; Jason Gorman; Hui Geng; Qingbo Liu; Yin Lin; Yaroslav Tsybovsky; Eden P Go; Barna Dey; Tsion Andine; Alice Kwon; Mit Patel; Deepali Gururani; Ferzan Uddin; Christina Guzzo; Raffaello Cimbro; Huiyi Miao; Krisha McKee; Gwo-Yu Chuang; Loïc Martin; Francesca Sironi; Mauro S Malnati; Heather Desaire; Edward A Berger; John R Mascola; Michael A Dolan; Peter D Kwong; Paolo Lusso
Journal:  Cell Host Microbe       Date:  2018-06-13       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.